PharmiWeb.com - Global Pharma News & Resources
29-Oct-2018

Global Lennox Gastaut Syndrome Epidemiology Forecast to 2027 - ResearchAndMarkets.com

The "Lennox Gastaut Syndrome - Epidemiology Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Lennox Gastaut Syndrome - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Lennox Gastaut Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Lennox Gastaut Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Lennox Gastaut Syndrome are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

According to this research, the prevalent cases of Lennox Gastaut Syndrome was 68,562 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Lennox Gastaut Syndrome with 31,772 prevalent cases in 2016 followed by Germany.

Lennox Gastaut Syndrome Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and seizure specific [Tonic, Myoclonic, Absence, Static, Partial].

Key Topics Covered:

1. Key Insights

2. Disease Overview: Lennox Gastaut Syndrome (LGS)

3. Epidemiology and Patient Population

4. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qwgjb5/global_lennox?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005344/en/

Editor Details

Last Updated: 29-Oct-2018